Comparative Pharmacology
Head-to-head clinical analysis: OXYBUTYNIN versus PRANTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYBUTYNIN versus PRANTAL.
OXYBUTYNIN vs PRANTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxybutynin is an anticholinergic agent that competitively antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the bladder detrusor muscle, inhibiting involuntary contractions and increasing bladder capacity.
Prantal (diphemanil methylsulfate) is a quaternary ammonium anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing gastrointestinal motility, gastric acid secretion, and bronchial secretions. It does not cross the blood-brain barrier.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (3 pumps) applied once daily.
50-100 mg orally 3-4 times daily; maximum 600 mg/day
None Documented
None Documented
Clinical Note
moderateOxybutynin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Fluconazole
Terminal half-life: 12-13 hours (range 7-20 hours) in healthy adults. In elderly, half-life may be prolonged due to reduced clearance.
Terminal elimination half-life is 4-6 hours; steady-state achieved within 24 hours in patients with normal renal function.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are mainly excreted renally (50%) and fecally (40%).
Primarily renal (50-70% unchanged) with minor biliary excretion; fecal elimination accounts for approximately 10-20%.
Category A/B
Category C
Anticholinergic
Anticholinergic
"The metabolism of Fluconazole can be decreased when combined with Oxybutynin."